The role of the immune system in the development of malignancies - The old problem, a new look;Rola uklładu immunologicznego w rozwoju nowotworów zlł;ośliwych - Stary problem, nowe spojrzenie

Onkologia i Radioterapia

Volumn 18, Issue 1, 2012, Pages 32-42

  Rybojad, Pawelł ^a   Jablonka, Andrzej ^a   Paprota, Krzysztof ^b   Tabarkiewicz, Jacek ^c  

^a Katedra i Klinika Chirurgii Klatki   (Poland)

^b Centrum Onkologii Ziemi Lubelskiej   (Poland)

^c Uniwersytetu Medycznego   (Poland)

Author keywords

Cancer; Immune system; Immunomodulation

Indexed keywords

HLA ANTIGEN;

CANCER CELL; CANCER CONTROL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LUNG CANCER; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NONHUMAN; REVIEW;

EID: 84862167452     PISSN: 18968961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. J Goła{ogonek}b, Jakóbisiak M, Lasek W, Stokłosa T.: Immunologia. PWN, Warszawa 2010
2. Male D, Cooke A, Owen M. Advanced immunology. Mosby, 2002
3. Chora{ogonek}ży M.: Molekularne aspekty karcynogenezy. Nowotwory 1997; 47: 251-263
4. Finn OJ.: Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
5. Mazzocoli G, Grilli M, Caroughi S i wsp.: Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol 2003; 16: 167-174.
6. Algarra I, Cabrera T, and Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61: 65-73.
7. Stary G, Bangert C, Tauber M i wsp.: Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007; 6:1441-1451.
8. Villablanca EJ, Raccosta L, Zhou D i wsp.: Tumormediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med 2010; 1: 98-105.
9. Briere B, Mores HL.: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 7: 506-520.
10. Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat Res 2005; 123: 89-111.
11. Dunn G, Old L, Schreiber R. The immunology of cancer immunosurveillance and Immunoediting. Immunity 2004; 21: 137-148.
12. Rock KL, Shen L.: Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 2005; 207:166-83.
13. Nikliński J, Hirsch Fred R. Molecular approaches to lung cancer evaluation Lung Cancer 2002; 38: 9-17.
14. Wojas K, Tabarkiewicz J, Jankiewicz M, Roliński J.: Dendritic cells in peripheral blood of patients with breast and lung cancer-a pilot study. Folia Histochem Cytobiol 2004; 1: 45-48.
15. Pardoll D.: Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21: 807-839.
16. Foukas PG, Tsilivakos V, Zacharatos P i wsp.: Expression of HLA-DR is reduced in tumor infiltrating immunocells (TIICs) and regional lymph nodes of non-smallcell lung carcinomas. A putative mechanism of tumorinduced immunosuppresion? Anticancer Res 2001; 21: 2609-2615.
17. Whiteside T. Immune responses to malignancies. J Allergy Clin Immunol 2010; 125: S272-83.
18. Khong H, Restifo N. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
19. Petersen RP, Campa MJ, Sperlazza J i wsp.: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107: 2866-2872.
20. Tabarkiewicz J, Roliński J.: Rola komórek dendrytycznych w patogenezie chorób człowieka i ich praktyczne wykorzystanie w immunoterapii. (Role of dendric cells in pathogenesis of human diseases and immunotherapy.) Acta Haemat. Pol 2006;. 37 supl. 1: 195-202.
21. Prehn RT, Prehn LM.: The flip side of immune surveillance: Immune dependency. Immunol Rev 2008; 222: 341-356.
22. Fulop T, Kotb R, Fortin CF i wsp.: Potential role of immunosenescence in cancer. Ann NY Acad 2010; 1197: 158-165.
23. Mlecnik B, Bindea G, Pages F, Galon J.:Tumor immunosuveillance in human cancers. Cancer Metastasis Rev 2011; 30: 5-12.
24. Huang FP, Chen YX, To CK.: Guiding the "misguided"-functional conditioning of dendritic cells for the DCbased immunotherapy against tumours. Eur J Immunol 2011; 1:18-25.
25. Tabarkiewicz J, Rybojad P, Jablonka A, Rolinski J.: CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol Rep. 2008; 1:237-243.
26. Rybojad P, Tabarkiewicz J, Koncewicz T i wsp.: Presence of CD25 antigen on lymphocytes of patients treated for non-small cell lung cancer (NSCLC).) Kardiochir. Torakochir. Pol. 2006; 3: 285-289.
27. Rabinovich GA, Gabrilovich D, Sotomayor EM.: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
28. Treilleux I, Blay JY, Bendriss-Vermare N i wsp.: Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 22: 7466-7474.
29. Dumitriu IE, Dunbar DR, Howie SE i wsp.: Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2009; 5: 2795-2807.
30. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V i wsp.: Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010; 2: 266-278.
31. Palucka K, Ueno H, Fay J i wsp.: Dendritic cells and immunity against cancer. J Intern Med. 2011; 269: 64-73.
32. Yang L, Pang Y, Moses HL.: TGF-â and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 16: 220-227.
33. Yie SM, Yang H, Ye SR I wsp.: Expression of human leukocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007; 58: 267-274.
34. Shevach EM.: Mechanisms of foxp3+T regulatory cellmediated suppression. Immunity 2009; 5: 636-645.
35. Nagaraj S, Gabrilovich DI.: Myeloidderived suppressor cells. Adv Exp Med Biol 2007; 601: 213-23.
36. Aspord C, Pedroza-Gonzalez A, Gallegos M i wsp.: Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007;14: 5:1037-1047.
37. Cramer DW, Finn OJ.: Epidemilogic perspective on immuno-surveillance in cancer. Current Opinion in Immuno 2011; 23: 265-271.
38. Panelli MC, Stashower ME, Slade HB i wsp.: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007; 1: R8.
39. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-1600.
40. Ilarregui JM, Croci DO, Bianco GA i wsp.: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 9: 981-991